Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hybrigenics, a Paris-based bio-pharmaceutical company into the research and development of new cancer treatments and specialised in protein interactions, has made its fee-for-service scientific activities into a fully-owned subsidiary named Hybrigenics Services SAS (Societe Anonyme Simplifiee).
Subscribe to our email newsletter
Hybrigenics got approval for the launch of Hybrigenics Services SAS subsidiary on June 25, 2010. The company said that this business generated EUR 3.27m revenue in 2009 and operates independently within Hybrigenics.
Hybrigenics is into the proprietary pharmaceutical R&D. The company claimed that its research on inhibitors of ubiquitin-specific proteases is at the forefront in the field of new anticancer agents acting on the ubiquitin-proteasome system. Selective inhibitors have been identified and protected by several patent applications.
Additionally, Hybrigenics’ Phase IIa clinical development study of Inecalcitol produced good results in terms of tolerance and presumption of efficacy in hormone-refractory prostate cancer. So far, 54 patients have been recruited for the trial.
Inecalcitol belongs to the class of vitamin D analogues. Vitamin D analogues are recognised for their role in cell proliferation and cell differentiation. Inecalcitol is a synthetic derivative of calcitriol, the natural active metabolite of vitamin D3.